FDA approvals and business deals were popular topics this week.

The U.S. Food and Drug Administration (FDA) has cleared the Ureteral Stent Company’s RELIEF ureteral stent to prevent vesicoureteral reflux, a major cause of patient discomfort. Ibex Medical Analytics also received 510(k) clearance for its Ibex Prostate Detect, an in vitro diagnostic medical device that harnesses AI to generate heatmaps identifying small and rare missed prostatic cancers. 

Also, Sequana Medical NV has received FDA Premarket Approval (PMA) to market alfapump as a treatment for recurrent or refractory ascites due to liver cirrhosis.

J&J MedTech is putting its Cerenovus stroke business up for sale, according to Financial Times (FT). According to reports, the sale is part of J&J’s efforts to reorganize its medical technology division, people familiar with the matter said.

Sotelix Endoscopy has closed a seed funding round with $1.7 million, which will fund R&D efforts and in vivo testing of its device.

1. J&J MedTech Reportedly Puts Stroke Care Biz Up for Sale
2. The RELIEF Ureteral Stent Gains FDA Clearance for Vesicoureteral Reflux
3. Sotelix Endoscopy Collects $1.7 Million in Seed Funding
4. Ibex Medical Analytics Gains FDA 510(k) Clearance
5. FDA Approves Sequana Medical’s alfapump for Refractory Ascites Treatment